一项发表于《柳叶刀·精神病学》的最新综述研究对21种抗抑郁药物的长期疗效进行了比较 123。结果显示,与氟西汀(fluoxetine)相比,艾司西酞普兰(escitalopram)、度洛西汀(duloxetine)和阿戈美拉汀(agomelatine)在改善长期抑郁症状方面可能更为有效 23。其中,艾司西酞普兰在防止抑郁症复发方面表现最佳 13。该分析纳入的随机对照试验涉及超过30,000名参与者,研究将“长期”定义为持续六个月或更久 2。此外,针对近万名被处方不同药物治疗长达一年的患者的大型分析显示,阿戈美拉汀和度洛西汀在预防复发方面的效果紧随艾司西酞普兰之后,而氟西汀的效果略低于前三者 3。这些药物还有助于患者维持治疗效果并减少中途停药率 2。
尽管发现了药物间的差异,专家强调这些差别幅度较小,且不能直接决定哪种药物对个体患者最有效 3。Radbound大学医学中心的Eric Ruhé教授指出,药物选择应因人而异 3。伦敦帝国理工学院的Sameer Jauhar博士也表示,患者不应仅依据此研究结果自行换药,而应与医生共同制定最适合个体的治疗方案 3。目前指南建议抑郁症缓解后至少继续服用抗抑郁药6个月 3,临床指南亦建议成年患者在治疗后至少继续服药六个月,最好十二个月 2。
这项研究的结论存在一定的局限性。鉴于部分原始研究存在高偏倚风险且“长期”定义有限,这些结果并非定论 2。超过一半纳入主要分析的原始研究被评估为具有高偏倚风险,且直接比较抗抑郁药的试验通常仅随访约六个月 2。现实情况也较为复杂,2022年的一项研究发现近四分之一开具处方的患者在两年后仍在接受处方,另一项研究显示平均服药时间长达四年 2。以澳大利亚为例,2024至2025年间有380万人获得抗抑郁药处方,其中艾司西酞普兰在药品福利计划(PBS)处方中排名第13位,度洛西汀排名第45位,而阿戈美拉汀不在PBS目录中 2。
A comprehensive analysis published in The Lancet Psychiatry compared the long-term effectiveness of 21 antidepressants, finding that escitalopram is superior to other common options in preventing depression relapse 13. The study indicates that while differences between medications exist, they are generally modest, and experts caution against patients switching drugs based solely on these rankings without medical consultation 3. Specifically, escitalopram showed the best performance for maintaining remission, followed by agomelatine and duloxetine, whereas fluoxetine ranked lower than these three 23.
The research draws on different datasets depending on the specific metric analyzed. One review synthesized data from 115 randomized controlled trials involving over 30,000 participants to compare long-term symptom relief, defining "long term" as treatment lasting six months or more 2. A separate large-scale analysis cited by BBC World focused on nearly 10,000 patients prescribed various medications for up to one year to specifically assess relapse prevention 3. In terms of clinical guidance, current recommendations suggest that adults with depression should continue medication for at least six months after remission, preferably for twelve months 23. However, real-world adherence varies; a 2022 study found that nearly a quarter of patients remained on prescriptions two years later, with an average treatment duration of four years 2.
Despite the statistical findings, researchers emphasize that individual response to antidepressants varies significantly. Professor Eric Ruhé from Radboud University Medical Center noted that drug choice must be personalized, while Dr. Sameer Jauhar of Imperial College London stated that the study cannot definitively tell doctors which drug works best for any single patient 3. Furthermore, limitations were acknowledged: more than half of the studies included in the primary analysis had a high risk of bias, and direct comparisons in previous trials often only tracked patients for about six months 2. In Australia, where 3.8 million people received antidepressant prescriptions in 2024–2025, escitalopram was the 13th most prescribed drug under the Pharmaceutical Benefits Scheme, while duloxetine ranked 45th and agomelatine was not listed on the scheme 2.
评论
还没有评论,欢迎留下第一条。